NCT07069699 2026-03-18
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT05442515 2026-03-12
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06395103 2026-03-11
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07109219 2026-03-04
ALLight
AstraZeneca
Phase 1/2 Recruiting
NCT06533579 2026-02-12
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06580301 2026-02-06
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2 Recruiting
NCT07134088 2026-01-29
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Recruiting
NCT05674175 2026-01-23
Co-administration of CART22-65s and huCART19 for B-ALL
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT06137118 2026-01-16
SYRUS
AstraZeneca
Phase 1/2 Recruiting
NCT05480449 2025-12-26
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT04150497 2025-09-09
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Phase 1/2 Recruiting
NCT05667506 2025-08-12
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Juventas Cell Therapy Ltd.
Phase 1/2 Recruiting
NCT06735495 2024-12-16
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Recruiting
NCT06635330 2024-10-10
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Kara Yakhteh Tajhiz Azma Company
Phase 1/2 Recruiting
NCT06503094 2024-07-16
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Recruiting
NCT05310591 2024-05-29
CAPTiRALL
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Recruiting